Renflexis (Infliximab-Abda) Patent Expiration, LOE Window & CMS Spending

Renflexis (Infliximab-Abda) by Samsung Bioepis: Biologic BLA (Purple Book Regime), 0 AB generics, $36.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSamsung Bioepis
FDA Application & PathwayB761054 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$36.9M
2024 Medicare Part D Spend$7.6M
2024 Medicaid Spend$29.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel